Perceptions of tick-borne encephalitis risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK

Cinzia Marano, PhD1*, Melissa Moodley, MDev2, Elaine Melander, BA (Hons)2, Laurence De Moerlooze, PhD1, and Hans D. Nothdurft, MD3

1GSK, 1300 Wavre, Belgium, 2Ipsos MORI, Ipsos Healthcare, E1W 1YW London, UK and 3Department of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany

*To whom correspondence should be addressed. GSK, Av. Fleming 20, Wavre, Belgium. Tel: +3210855211, Email: cinzia.x.marano@gsk.com
†A video to accompany this article is available in the online version of this article.

Submitted 14 June 2018; Revised 24 July 2018; Editorial decision 26 July 2018

Abstract

Background: While the worldwide endemicity of tick-borne encephalitis (TBE) has been increasing, a lack of awareness of the risks of this life-threatening disease may be leading to an underutilization of preventive measures among travellers to TBE-endemic regions. This study’s objectives were to assess travellers’ awareness of TBE and advice-seeking attitudes, and to evaluate practices of travel clinics regarding pre-travel advice.

Methods: We used an online questionnaire to identify individuals aged 18–65 years residing in the UK, Germany, Canada and Sweden, who had travelled to TBE-endemic countries between 2013 and 2016. This sample was defined as the visit-risk sample. Of these, the first 375 respondents who reported that they had engaged in pre-defined at-risk activities (e.g. hiking in forests) were asked to complete an additional online survey and were included in the activity-risk sub-sample. We also used an online/phone questionnaire to interview travel clinic personnel.

Results: The TBE visit-risk sample included 4375 individuals; 69% had heard of the disease and 32% had heard of a TBE vaccine. Before travelling, travellers most commonly sought information online (26%); fewer travellers consulted family doctors (8%) or travel clinics (5%). In the activity-risk sample, 79% of the travellers were aware of at least one correct TBE prevention measure; however, only 15% reported being vaccinated within the past 3 years, with 11% of vaccinated travelling doing so following a clinic’s recommendation. One hundred and eighty travel clinic representatives responded and reported that TBE vaccination was recommended to an average of 61% of travellers to endemic regions. Vaccination-reminder services such as follow-up appointments, e-mail and text reminders were offered by 50% of the clinics.

Conclusions: There is a need to increase awareness of the risk and prevention of TBE among travellers to endemic countries, and travel clinics could play an important role in this process.

Key words: TBE, endemic, vaccination, traveller, travel clinic

Background

Tick-borne encephalitis (TBE) is a viral infection caused by the TBE virus (TBEV) of the family Flaviviridae; three of the TBEV subtypes are known to cause disease in humans.1,2 The virus is predominantly transmitted through the bite of an infected tick or, in rare cases, through consumption of unpasteurized dairy products.2 The majority of infected individuals remain asymptomatic after the bite, but about 10% of cases develop central nervous system involvement, such as meningitis, encephalitis or myelitis.2,3 Case–fatality ratios vary from 0.52% for infections caused by European strains, to up to 35% for the Far Eastern TBE virus subtype.3
TBE is endemic across large regions of Europe (in regions of more than 27 countries), Russia and parts of Asia. The incidence of the disease varies considerably between and even within close geographical regions. In Europe, 1500–3500 TBE cases are reported each year, although this figure is probably underestimated, as disease notification is not mandatory in all countries. Most cases occur between April and November, with peaks in the summer associated with intense feeding periods during stages of tick development.

There is no specific treatment for TBE; however, the disease is vaccine preventable. The World Health Organization recommends vaccination against TBE for people living in risk areas, individuals with occupational risks and travellers to endemic areas, particularly if their visits include outdoor activities.

The incidence of TBE in many countries/geographical areas appears to have increased over the past 30 years. An overall escalation in international tourist arrivals has also been reported, with Europe experiencing a 5% increase in visiting tourists. However, travellers are generally unaware of the disease and the majority do not seek any pre-travel advice, or comply with current recommendations when travelling to TBE-endemic regions.

In this study, we assessed travellers’ advice-seeking attitudes and awareness of TBE and prevention measures. We also attempted to evaluate practices of travel clinics regarding pre-travel advice.

**Methods**

We conducted a questionnaire survey between October and November 2016, which enrolled participants from Canada, Germany, Sweden and UK. The full survey included travellers to TBE- or rabies-endemic regions. Here, we provide the results of the TBE survey. The study methodology is detailed in Supplement 1.

**Traveller survey**

We invited respondents aged 18–65 years who had travelled to rabies or TBE-endemic countries in the previous 3 years (visit-risk sample) to complete a 5-min questionnaire. The questionnaire consisted of closed-end questions on travel destinations, preparation for trips and activities, familiarity with travel clinics, awareness and level of concern over TBE and knowledge of preventive measures, including vaccines against TBE. Among the 375 first respondents, a subset of the visit-risk sample who had engaged in high-risk activities completed an additional 15-min survey (activity-risk subsample). We considered high-risk activities to be trips that took place between April and November and involved hiking or camping in forests, or cycling/mountain biking. Respondents previously vaccinated against TBE solely due to their residency in a TBE-endemic region were excluded from the survey. The activity-risk questionnaire included both open- and closed-end questions on the perceived risk of TBE and advice-seeking attitudes, as well as knowledge and practice of preventive measures.

**Travel clinic survey**

We also surveyed healthcare providers (HCPs; nurses or doctors) working in travel clinics. A screening questionnaire was used to assess their eligibility, with the following inclusion criteria: at least 3 years’ experience of working in a travel clinic, a minimum of 10 h per week spent working in a travel clinic (10 h per month in Sweden), and responsibility for advising on and making decisions about travel vaccination. The questionnaire contained closed- and open-ended questions exploring travel clinics’ practices on pre-travel advice, including risk assessment and prevention recommendations.

The target sample size for the visit-risk survey was >4000 individuals (1000 in each country), and a quota of 375 individuals was pre-defined for the activity-risk survey.

The HCP and traveller data were analysed separately.

**Results**

**Visit-risk sample**

Of the 29 860 screened respondents, 22 910 (77%) met the initial inclusion criteria and 8943 (39%; total visit-risk sample) had visited a rabies or TBE-endemic country and completed the visit-risk questionnaire. Among them, 4375 respondents had visited a TBE-endemic country and were included in the TBE visit-risk sample (Figure 1); a summary of their characteristics is shown in Supplement 2.

The five most frequent TBE-endemic destinations were Germany (visited by 37% of travellers), France (34%), Italy (24%), Denmark (19%) and Greece (17%). The majority of trips took place in July and August.

In the visit-risk sample of travellers to TBE-endemic regions (4 375), 26% prepared for the trip by searching for information online. Other sources of information were reported less

Figure 1. Flow diagram of screened individuals and respondents. TBE, tick-borne encephalitis; N, number of respondents; UK, United Kingdom. Note: *the first 375 respondents who had visited a TBE-endemic country took part in high-risk activities and had completed the visit-risk questionnaire were invited to complete the activity-risk questionnaire.
frequently, including talking to friends and family who had previously visited the same country (9%), talking to a family doctor (8%), pharmacist (5%), or a travel (5%) or other type (4%) of clinic. Only 14% of travellers to TBE-endemic countries were aware that travel clinics provided travel vaccines, and 52% of respondents were unaware of the existence of travel clinics. Regarding awareness, 24% said they knew a few basic facts about TBE, 10% said they had a good knowledge of TBE, 17% had some understanding and 31% had never heard of the disease. Only a third of TBE visit-risk travellers (32%) were aware of a TBE vaccine, with awareness being higher in Sweden (70%) and lower in Canada (10%) and the UK (12%).

Activity-risk sub-sample
The TBE activity-risk sub-sample included 375 travellers who completed the activity-risk questionnaire (Figure 1). The average age of the respondents was 41 years; 57% were male and 63% were frequent travellers (Table 1).

Overall, a quarter of the respondents were not aware of TBE at all, although this percentage varied by country, ranging from 36% and 34% in the UK and Canada, respectively, down to 0% in Sweden (Figure 2).

Considering all the trips they had taken to TBE-endemic countries in the past three years, only 14% of the visit-risk sample had ever felt at high risk of TBE on at least one trip and 26% had never felt at risk on any of their trips. Swedes (21%) and Germans (20%) were more likely to have felt at risk, and this percentage was higher among TBE-vaccinated respondents (36%). The perception of risk of TBE was similar among travellers to Europe or Asia (Table 2).

Table 1. Characteristics of respondents to the activity-risk questionnaire (N = 375)

|                        | Canada  | Germany | Sweden | UK     | Total |
|------------------------|---------|---------|--------|--------|-------|
| Mean age, years        | 43      | 41      | 40     | 41     | 41    |
| Age group, %           |         |         |        |        |       |
| 18–25 years            | 8       | 14      | 17     | 8      | 11    |
| 26–35 years            | 24      | 22      | 25     | 32     | 25    |
| 36–45 years            | 36      | 22      | 25     | 28     | 28    |
| 46–55 years            | 12      | 32      | 23     | 15     | 20    |
| 56–65 years            | 20      | 10      | 13     | 17     | 15    |
| Male, %                | 62      | 55      | 55     | 56     | 57    |
| Travel habits, %       |         |         |        |        |       |
| Frequent traveller     | 44      | 69      | 88     | 58     | 63    |
| Occasional traveller   | 34      | 23      | 11     | 29     | 25    |
| Infrequent traveller   | 22      | 8       | 1      | 13     | 12    |
| Highest level of formal education, % |         |         |        |        |       |
| Grade school or some high school | 7       | 4       | 3      | 3      |
| Completed high school  | 7       | 20      | 35     | 14     | 18    |
| Technical or trade school / community college | 8       | 9       | 8      | 16     | 10    |
| Community college or university, but did not finish | 10      | 25      | 9      | 8      | 13    |
| Complete university degree (e.g. Bachelor's) | 44      | 25      | 35     | 43     | 37    |
| Post-graduate degree (e.g. Master's or PhD) | 31      | 14      | 9      | 16     | 18    |
| Employment status, %   |         |         |        |        |       |
| Employed full-time     | 76      | 67      | 69     | 68     | 70    |
| Employed part-time     | 13      | 15      | 15     | 22     | 16    |
| Not employed           | 3       | 12      | 13     | 5      | 8     |
| Retired                | 8       | 6       | 3      | 5      | 6     |

N, number of respondents; %, percentage of respondents in each category; UK, United Kingdom.
Healthcare provider sample

A total of 180 travel clinic respondents were included in the survey (47 from Canada, 33 from Sweden and 50 from each Germany and the UK). Respondents were doctors (62%) or nurses (38%), with an average 12 years in practice.

When assessing the risks of TBE associated with travel, 76% of HCPs inquired about the travellers planned activities and 76% about the TBE-endemicity of the travel area, while only 23% of HCPs questioned the traveller on the season and 17% on the length of the travel. Only 58% of HCPs agreed that TBE vaccination should be considered as a travel vaccine for those going to endemic countries. Travel clinics recommended TBE vaccination to 61% of travellers to TBE-endemic countries, ranging from 47% in Sweden to 78% in Germany.

The main reasons for recommending TBE vaccination to travellers were planned outdoor activities (for 75% of HCPs), travel to rural areas (58%), multiple destinations (54%), length of trip (48%) and travel to remote areas (46%). HCPs most commonly supported their recommendation by giving information about the risks and complications of TBE (30%), or the seriousness of the disease (22%); 21% also mention the benefits of vaccination and 76% offer advice on prevention measures.

In our study, travel clinics considered that 81% of travellers generally complete a recommended vaccination schedule, and use several types of reminders. Among TBE-vaccinated travellers, the most reported reminders were vaccination cards (for 49% travellers), scheduled follow-up appointments (47%) or vaccination wallet reminder cards (44%) (Table 4).

The HCPs and the travellers gave different weight to reasons for not getting vaccinated, although the main reason was considered the lack of a high risk by both HCPs and travellers (Table 5).
Discussion

This questionnaire-based study is one of the first to assess the perception of international travellers and travel clinic HCPs on TBE, a neglected disease despite the known health risks in common tourist destinations in Europe and Asia.

In our study, the profile of the activity-risk sub-sample was based on the at-risk traveller population, for which the World Health Organization currently recommends vaccination against TBE before travelling.\(^1\)\(^4\)\(^17\) Although current TBE vaccines provide good protection, and are generally well-tolerated,\(^1\)\(^8\) only 35% of the activity-risk sub-sample were aware of a vaccine, and only 15% reported being vaccinated. Vaccine uptake for TBE vaccine appears to be low compared with other travel vaccines against infectious diseases. For example, in a sample of travellers similar (for hepatitis A and B) to the visit-risk travellers in this study, 72% were aware of vaccines for hepatitis A and B.\(^1\)\(^8\) However, in the present study, only 32% of the visit-risk sample were aware of a vaccine for TBE, and this was mainly driven by increased awareness from countries with TBE-endemic regions (Germany and Sweden). Moreover, among the HCPs, only 58% agreed that TBE vaccination should be considered as a travel vaccine for those going to endemic countries/regions. For travellers in the activity-risk sub-sample who were vaccinated, adherence to the vaccination schedule observed was also low, with only half of those who could remember, completing a three-dose series and around a third receiving two doses.

From a HCP’s perspective, TBE vaccination was recommended to 61% of travellers. Both HCPs and travellers reported that the main reason for refusing vaccination was the perception that the risk of TBE was not high enough. This was also the most important reason given for declining immunization in Sweden, as reported in a recent study in 8 000 individuals living

| Table 4. Vaccination-reminder services offered by travel clinics and their use among activity-risk travellers |
| --- |
| Reminder | Travellers vaccinated against TBE | Travel clinics |
| Offered, used | Offered, not used | Not offered | Offered |
| Written on vaccination card/booklet | 49 | 18 | 22 | not answered |
| Follow-up appointment (scheduled at 1st injection) | 47 | 5 | 31 | 50 |
| Vaccination wallet reminder card | 44 | 13 | 31 | 37 |
| Reminder phone calls | 20 | 15 | 51 | 35 |
| A web key tool* | 18 | 11 | 58 | Not answered |
| An e-mail/text | 18 | 20 | 45 | 38 |
| A website (requiring registration) | 9 | 16 | 58 | 10 |
| A vaccine app for smartphone | 9 | 13 | 64 | 8 |

TBE, tick-borne encephalitis.
Note: *A plug-in tool which linked the traveller to a reminder website, provided by a pharmacy.

| Table 5. Main reasons for not taking TBE vaccination, from the travellers and HCPs’ perspective |
| --- |
| Travellers (activity-risk sub-sample) | Travel clinics |
| All, % | Visited a HCP before travel, % | Reason | % |
| N = 320 | Yes (N = 94) | No (N = 226) | N = 320 | Travellers do not consider TBE risk high enough | 60 |
| TBE risk was not high enough to need vaccination | 34 | 29 | 37 | Travellers have been to the same country before | 48 |
| Never really thought about it | 27 | 16 | 31 | Travellers did not have enough time | 44 |
| Nobody told them to get vaccinated | 23 | 16 | 25 | Vaccination safety/side-effects concerns | 42 |
| Did not have enough information | 15 | 14 | 16 | Vaccine is too expensive | 39 |
| Lack of time/logistical burden | 11 | 23 | 6 | Travellers do not like needles | 38 |
| Had been to the same location before | 10 | 9 | 10 | Vaccine schedule is too arduous | 34 |
| Uncertainty on whether the vaccine is effective | 10 | 14 | 8 | Vaccination takes too much time | 32 |
| Their doctor/nurse/pharmacist did not suggest it | 9 | 14 | 8 | Travellers are not sure if vaccine is effective | 28 |
| Did not find out about it until after their travel | 8 | 15 | 6 | Vaccination cost not reimbursed | 23 |
| Cost burden | 8 | 15 | 5 | Travellers do not feel sufficiently informed on the vaccine | 17 |

TBE, tick-borne encephalitis; HCP, healthcare provider; N, number of respondents; %, percentage of respondents in each category.
in a region where vaccination is recommended by local authorities. Travellers often cited lack of information as a reason for not being vaccinated, while HCPs did not consider this was an important factor in following recommendations. Consistent with previous studies, the HCPs in our survey may have underestimated the incidence of TBE, so it is important that they keep up-to-date with recommendations on TBE to travellers to endemic countries. Vaccination side-effects were perceived as an important reason for vaccine refusal from the travel clinic perspective but not by travellers. In addition, although TBE cases occur between April and November, only 23% and 17% of HCPs included the season and length of trip, respectively, in their top three important components of a TBE risk assessment.

Adherence to the three-dose schedule in our study was 50% based on travellers’ recall. To improve compliance with the vaccination schedule, follow-up appointments and vaccination cards were used more often by travellers than emails, texts or phone calls. This finding was in-line with observations in the rabies sample (Marano et al. published in this issue) as well as in a previous study that assessed the use of reminders in travellers vaccinated against hepatitis. However, although completion of a series of vaccinations (two or three doses) is needed by at least 3 weeks before exposure, only about half of travel clinics offered reminder services.

Understanding of the relationship between travel and vaccination is limited because previous studies have tended to sample from travel clinics or airports, which would reflect travellers rather than the general public. Airport surveys may over-represent frequent travellers and are also limited to air travellers, not necessarily capturing inter-Europe travel to TBE-endemic areas, which may also be via rail, car or water. A key strength of our methodology is that it captures travellers to endemic countries, including frequent travellers. However, selection bias is inherent in a self-selected sample, and the online format of the questionnaire meant that the population was limited to those with Internet access. Selection bias was also a limitation of the travel clinic survey. A further limitation was that feedback during the recruitment phase with travel clinic respondents suggested that the concept of ‘travel clinics’ does not exist in Sweden, rather travellers are more likely to attend vaccination sessions at their local health centre.

Conclusions
Knowledge of TBE varied across the countries studied, with a clear link to TBE-endemicity and travellers from Canada and UK having the lowest awareness. Seeking online information was a common step in travel preparation, suggesting that improving online resources about TBE might increase awareness among travellers. However, for travellers who were vaccinated, many did not complete the vaccination course, suggesting that better vaccination-reminder systems are needed. In addition, more could be done to offer travel clinics better evidence-based tools to help communicate the need for vaccination, including the increased risk of exposure to TBE during summer peaks in endemic countries.

Supplementary data
Supplementary data at JTM online.

Funding
This work was supported by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis; and paid all costs associated with developing and publishing the manuscript.

Acknowledgements
The authors would like to thank all study participants and Frédérique Wiot for their contribution to the study. We also thank Annick Moon (freelance medical writer c/o GSK Vaccines) and Petronela M. Petrar (XPE Pharma & Sciences c/o GSK Vaccines) for providing medical writing support and Susana Montenegro Gouveia (XPE Pharma & Sciences c/o GSK Vaccines) for assisting with publication management and editorial support. The authors would like to thank the following people for the support of the accompanying video: Jany Feng (MediTech Media, part of Nucleus Global) and Jenny Lustin (MediTech Media, part of Nucleus Global) for medical writing support, David Patching (Synaptik Digital, part of Nucleus Global) for the creative development and Piers Bishop (piersbishop.com) for providing narration.

Author Contributions
All authors participated in the conception or design of the study and the interpretation of the results. All authors had full access to the data, were involved in the drafting this manuscript, gave final approval before submission and are accountable for all aspects of the work. In addition, Melissa Moodley and Elaine Melander participated in the acquisition/assemblying of data and provided statistical expertise. Melissa Moodley, Elaine Melander, Cinzia Marano, Laurence De Moerlooze and Hans Nothdurft performed/supervised the analysis.

Conflict of interest: C.M. is an employee of GSK and owns restricted shares in GSK as part of her employee remuneration. L.M.D. was an employee of GSK at the time the study was conducted and is now employed by Takeda. M.M., E.M. and H.N. have no conflict of interest to disclose.

Previous presentations in conferences/congresses
Cinzia Marano, Melissa Moodley, Laurence De Moerlooze, Hans Nothdurft. Risky Travel? Travellers’ Awareness of Rabies and Tick-borne Encephalitis and Factors Influencing Their Health Choices. Poster presentation, 15th conference of the International Society of Travel Medicine (CISTM15), Barcelona, Spain, 14–18 May 2017.

Funding
GlaxoSmithKline Biologicals SA funded this study and the development of the manuscript.

References
1. Vaccines against tick-borne encephalitis. WHO position paper. Wkly Epidemiol Rec 2011; 86:241–56.
2. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet 2008; 371:1861–71.
3. Ruzek D, Dobler G, Donoso Mantke O. Tick-borne encephalitis: pathogenesis and clinical implications. Travel Med Infect Dis 2010; 8:223–32.
4. Steffen R. Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on
5. European Centre for Disease Control and Prevention. Epidemiological situation of tick-borne encephalitis in the European Union and European Free Trade Association countries. Available at: http://www.ecdc.europa.eu/en/publications/Publications/TBE-in-EU-EFTA.pdf [accessed 7 August 2017].

6. Lindquist L. Tick-borne encephalitis. In: Tselis AC, Booss J (eds). Handbook of Clinical Neurology; Vol. 123. Amsterdam: Elsevier B. V, 2014, pp. 531–59.

7. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2014 – Emerging and Vector-Borne Diseases ECDC, Stockholm, 2014. Available at: http://ecdc.europa.eu/en/publications/Publications/emerging-vector-borne-diseases_annual-epidemiological-report-2014.pdf [accessed 10 April 2017].

8. Bogovic P, Strle F. Tick-borne encephalitis: a review of epidemiology, clinical characteristics, and management. World J Clin Cases 2015; 3:430–41.

9. Dobler G, Gniel D, Petermann R, Pfeffer M. Epidemiology and distribution of tick-borne encephalitis. Wien Med Wochenschr 2012; 162:230–8.

10. European Centre for Disease Prevention and Control (ECDC). Technical report. Epidemiological situation of tick-borne encephalitis in the European Union and European Free Trade Association countries. 2012. Available at: http://www.ecdc.europa.eu/en/publications/Publications/TBE-in-EU-EFTA.pdf [accessed 10 April 2017].

11. Kunze U Tick-borne encephalitis-still on the map: Report of the 18th annual meeting of the International scientific working group on tick-borne encephalitis (ISW-TBE). TICKS Ticks Borne Dis. 2016; 7:911–4.

12. Banzhoff A, Broker M, Zent O. Protection against tick-borne encephalitis (TBE) for people living in and travelling to TBE-endemic areas. Travel Med Infect Dis 2008; 6:331–41.

13. Kollaritsch H, Paulke-Korinek M, Holzmann H, Hombach J, Bjorvatn B, Barrett A. Vaccines and vaccination against tick-borne encephalitis. Expert Rev Vaccines 2012; 11:1103–19.

14. Smit R, Postma MJ. Review of tick-borne encephalitis and vaccines: clinical and economical aspects. Expert Rev Vaccines 2015; 14: 737–47.

15. Haditsch M, Kunze U. Tick-borne encephalitis: a disease neglected by travel medicine. Travel Med Infect Dis 2013; 11:295–300.